New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance
September 11, 2023 06:30 ET
|
ENA Respiratory
– INNA-051 increased early expression of multiple antiviral effector genes compared with placebo and shortened viral shedding duration in participants with confirmed influenza infection MELBOURNE,...
ENA Respiratory Expands Leadership Team and Extends U.S. Department of Defense Funding to Enable Phase II Program of INNA-051 in Community-Acquired Viral Respiratory Infections
August 29, 2023 08:00 ET
|
ENA Respiratory
-- New $3.8 million DOD contract extension will fund non-clinical safety studies to support a three-month seasonal prophylaxis Phase 2b study in at-risk populations, comprising elderly individuals...
Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study
February 13, 2023 08:00 ET
|
ENA Respiratory
-- Post hoc analyses found a statistically significant reduction in the duration of flu infection and a dose-related trend toward a reduction in symptom duration. -- These results support the further...
Survey demonstrates that individuals with COPD seek more options to reduce risks of seasonal respiratory viral infections
January 30, 2023 08:00 ET
|
ENA Respiratory
-- ENA Respiratory and COPD Foundation survey confirms patients are overwhelmingly positive about taking an immune-modulating nasal spray to reduce lung disease exacerbations---- Survey was conducted...
ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051
January 09, 2023 08:00 ET
|
ENA Respiratory
-- Goal is to add new medical countermeasure (MCM) against known and emerging viral respiratory threats MELBOURNE, Australia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Clinical-stage pharmaceutical company...
ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray
May 11, 2022 08:00 ET
|
ENA Respiratory
SYDNEY, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for...
First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray
March 15, 2022 08:00 ET
|
ENA Respiratory
ENA Respiratory begins influenza challenge study for fast-acting nasal spray INNA-051, designed to boost innate immunity in patients at high risk of severe complications from respiratory infections ...
ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray
February 23, 2022 08:00 ET
|
ENA Respiratory
-- INNA-051 is being developed to stimulate innate immunity and reduce the incidence and severity of respiratory viral infections, such as COVID-19, rhinovirus, or influenza in populations at-risk of...
First-in-Class, Broad-Spectrum Nasal Spray to Prevent COVID-19 and Other Common Respiratory Illnesses Set to Begin Phase 2 Trials
September 28, 2021 08:00 ET
|
ENA Respiratory
-- ENA Respiratory engages PPD, Inc. for Phase 2 COVID-19 post-exposure prophylaxis study and hVIVO for influenza challenge study to assess the efficacy of fast-acting nasal spray designed to boost...
ENA Respiratory Begins Phase I Study of COVID-19 Preventative Nasal Spray Designed to Stimulate Body’s Firstline Immune Defense in the Nose
July 13, 2021 08:00 ET
|
ENA Respiratory
-- First-in-class, fast-acting nasal spray designed to boost innate immunity against respiratory viruses including SARS-CoV-2 and its variants, influenza and the common cold at the first entry portal...